FdaApplication
NDA 219015
Identifiers
- fda_app_no: NDA219015
Properties
| Property | Value |
|---|---|
| applicant_name | JOURNEY MEDICAL CORP |
| application_type | NDA |
| approval_date | 2024-11-01 |
Revenue by product
EMROSI
| Period | Revenue |
|---|---|
| Q2 2026 | $8.1M |
| Q1 2026 | $6.3M |
| Q4 2025 | $5.0M |
| Q3 2025 | $4.9M |
| Q2 2025 | $2.8M |
| Q1 2025 | $2.1M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| EMROSI | MINOCYCLINE HYDROCHLORIDE | EQ 40MG BASE | CAPSULE, EXTENDED RELEASE;ORAL |
1 product